Consequently, clinical guidelines developed for the management of sepsis prior to the emergence of COVID-19 may not be fully applicable to critically ill COVID-19 patients (e.g., the use of glucocorticoids or IL-6 monoclonal antibody such as tocilizumab). This evidence concerns the gene IL6 and COVID-19.